Select your country »

HealthEase Insights NAFLD Insert
Educational Resources

HealthEase Insights NAFLD Insert

HealthEase Insights NAFLD Insert

Published: 2018-01-16
File Size: 2,201 KB
Author: BioCeuticals

Non-alcoholic fatty liver disease (NAFLD), encompassing both non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), is the most common cause of liver disease in Australia. There is increasing evidence for considering NAFLD as part of metabolic syndrome including obesity, hyperinsulinaemia, insulin resistance, hypertriglyceridaemia and hypertension. Obesity is a clear risk factor for developing this common condition. The conventional therapeutic approach to NAFLD is based on lifestyle intervention, but there is no consensus on the ideal pharmacological treatment.

Chat online with our team now

Patient support

If you are a patient or consumer, please contact your healthcare practitioner or pharmacist for advice, or find your nearest practitioner here.

Practitioner support

Log me In